Technology & Science
Nov. 6, 2010
New DOJ Position on Patenting Genes
For the first time, the U.S. Court of Appeals for the Federal Circuit is considering whether DNA isolated in a lab is a product of nature or material nurtured out of its natural setting then altered for therapeutic purposes and therefore wo
Daily Journal Staff Writer
Call it the ultimate case of nature versus nurture.
For the first time, the U.S. Court of Appeals for the Federal Circuit is considering whether DNA isolated in a lab is a product of nature or a material manipulated outside of its natural setting for therapeutic purposes and therefore worthy of a patent.
The case already had high stakes for biotechnology companies looking to profit from gen...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In